Company profile: Faron Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies targeting acute organ trauma, vascular damage, and cancer immunotherapy, including bexmarilimab, a humanized monoclonal antibody against Clever-1 on macrophages to modify the tumor microenvironment and boost anti-tumor immune response, and Traumakine, an intravenous interferon beta-1a to prevent multiorgan dysfunction and mitigate CAR-T side effects (cytokine release syndrome, neurotoxicity).
Products and services
- Clinical-stage Therapeutic Pipeline: Program engineers novel treatments for acute organ traumas, vascular damage, and cancer immunotherapy, focused on significant unmet medical needs
- Bexmarilimab: Humanized monoclonal antibody targets Clever-1 on macrophages, modifying the tumor microenvironment to stimulate immune responses against cancer
- Traumakine: Therapy using intravenous interferon beta-1a to prevent multiorgan dysfunction and mitigate CAR-T side effects like cytokine release syndrome and neurotoxicity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Faron Pharmaceuticals
Arsanis
HQ: Austria
Website
- Description: Provider of biopharmaceutical infectious disease treatments based on bacterial protein and carbohydrate antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arsanis company profile →
Oncoinvent
HQ: Norway
Website
- Description: Provider of radiopharmaceutical cancer treatments, including Radspherin for metastatic cancers in body cavities using alpha-emitting microparticles. Operates a GMP-standard facility for radiopharmaceutical production supporting large multi-center clinical studies. Develops a pipeline of radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products, with proprietary antibodies as targeting modules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncoinvent company profile →
Orega Biotech
HQ: France
Website
- Description: Provider of immunotherapeutic monoclonal antibodies for cancer, including IPH5201, a humanized CD39 blocking antibody that inhibits adenosine production and is in Phase 2 trials for non-small cell lung cancer, and a novel preclinical human-mouse cross-reactive blocking antibody that improves the efficacy of anti-PD-1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orega Biotech company profile →
Quest PharmaTech
HQ: Canada
Website
- Description: Provider of antibody-based immunotherapeutic products for cancer and photodynamic therapy technology for oncology and dermatology, including Oregovomab, an antibody-based immunotherapy in clinical trials for ovarian cancer, and truncated MUC16-targeting Mab AR 9.6 as a theranostic agent.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quest PharmaTech company profile →
Telesta Therapeutics
HQ: Canada
Website
- Description: Provider of transformative human therapeutics, focused on licensing, acquisition, development, manufacturing and commercialization of novel medicines addressing major unmet medical needs, particularly in oncology; anchor product MCNA has completed a Phase III pivotal study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telesta Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Faron Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Faron Pharmaceuticals
2.2 - Growth funds investing in similar companies to Faron Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Faron Pharmaceuticals
4.2 - Public trading comparable groups for Faron Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →